Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Cancer Research
|
March 5, 2025
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma
Kelly M Mahuron, Osmaan Shahid, Prachi Sao, et al.
The Journal of Clinical Investigation
|
August 16, 2016
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I Daud, Kimberly Loo, Mariela L Pauli, et al.
Cell
|
April 9, 2019
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4<sup>+</sup> T Cell Immunity
Mikhail Binnewies, Adriana M Mujal, Joshua L Pollack, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
BJC Reports
|
November 8, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, et al.
The Journal of Experimental Medicine
|
June 16, 2020
Layilin augments integrin activation to promote antitumor immunity
Kelly M Mahuron, Joshua M Moreau, Jeff E Glasgow, et al.
The Journal of Experimental Medicine
|
March 2, 2021
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Kristen E Pauken, Osmaan Shahid, Kaitlyn A Lagattuta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Immunity
|
September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity
|
December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Cancer Research
|
March 5, 2025
Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma
Kelly M Mahuron, Osmaan Shahid, Prachi Sao, et al.
The Journal of Clinical Investigation
|
August 16, 2016
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I Daud, Kimberly Loo, Mariela L Pauli, et al.
Cell
|
April 9, 2019
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4<sup>+</sup> T Cell Immunity
Mikhail Binnewies, Adriana M Mujal, Joshua L Pollack, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
BJC Reports
|
November 8, 2024
Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response
Zoe Quandt, Saya Jacob, Muhammad Zaki Hidayatullah Fadlullah, et al.
The Journal of Experimental Medicine
|
June 16, 2020
Layilin augments integrin activation to promote antitumor immunity
Kelly M Mahuron, Joshua M Moreau, Jeff E Glasgow, et al.
The Journal of Experimental Medicine
|
March 2, 2021
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment
Kristen E Pauken, Osmaan Shahid, Kaitlyn A Lagattuta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
Adil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Immunity
|
September 14, 2022
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Immunity
|
December 16, 2018
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, et al.
Page
of 9